Trends and challenges in behavioural phenotype research

Journal of Intellectual Disability Research

Volumn 51, Issue 9, 2007, Pages 649-652

  Oliver, Chris ^a   Hagerman, Randi ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOBAM; GANAXOLONE; METABOTROPIC RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR GENETICS; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DE LANGE SYNDROME; DEVELOPMENT; DISEASE SEVERITY; DOWN SYNDROME; EDITORIAL; FRAGILE X SYNDROME; GENETIC DISORDER; HUMAN; HYPERPHAGIA; INTELLECTUAL IMPAIRMENT; LIFE EXPECTANCY; MEDICAL RESEARCH; MENTAL DISEASE; NONHUMAN; PHENOTYPE; PRADER WILLI SYNDROME; PREDICTION;

EID: 34547884991     PISSN: 09642633     EISSN: 13652788     Source Type: Journal    
DOI: 10.1111/j.1365-2788.2007.00987.x     Document Type: Editorial

References (15)

1. Arocena D. G., Iwahashi C. K., Won N., Beilina A., Ludwig A. L., Tassone F., Schwartz P. H. & Hagerman P. J. (2005) Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Human Molecular Genetics 14, 3661-71.
2. Bear M. F., Huber K. M. & Warren S. T. (2004) The mGluR theory of fragile X mental retardation. Trends in Neurosciences 27, 370-7.
3. Coffey S. M., Cook K., Tartaglia N., Tassone F., Nguyen D. V., Pan R., Bronsky H. E., Yuhas J., Borodyanskaya M., Grigsby J., Hagerman P. J. & Hagerman R. J. (0000) Expanded clinical phenotype of women with the FMR1 premutation. American Journal of Medical Genetics (in press).
4. D'Hulst C., De Geest N., Reeve S. P., Van Dam D., De Deyn P. P., Hassan B. A. & Kooy R. F. (2006) Decreased expression of the GABAA receptor in fragile X syndrome. Brain Research 1121, 238-45.
5. Farzin F., Perry H., Hessl D., Loesch D., Cohen J., Bacalman S., Gane L., Tassone F., Hagerman P. & Hagerman R. (2006) Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. Journal of Developmental and Behavioral Pediatrics 27, S137-44.
6. Hagerman R. J. (2006) Lessons from fragile X regarding neurobiology, autism, and neurodegeneration. Journal of Developmental and Behavioral Pediatrics 27, 63-74.
7. Hagerman P. J. & Hagerman R. J. (2004) The fragile-X premutation: A maturing perspective. American Journal of Human Genetics 74, 805-16.
8. Karmiloff-Smith A., Thomas M. S. C., Annaz D., Humphreys K., Ewing S., Grice S., Brace N., Van Duuren M., Pike G. & Campbell R. (2004) Exploring the Williams syndrome face processing debate: The importance of building developmental trajectories. Journal of Child Psychology and Psychiatry and Allied Disciplines 45, 1258-74.
9. Morton (2004) Understanding Developmental Disorders: A Causal Modelling Approach. Blackwell, Oxford.
10. Nowicki S. T., Tassone F., Ono M. Y., Ferranti J., Croquette M. F., Goodlin-Jones B. & Hagerman R. J. (2007) The Prader-Willi phenotype of fragile X syndrome. Journal of Developmental and Behavioral Pediatrics 28, 133-8.
11. Porter R. H., Jaeschke G., Spooren W., Ballard T. M., Buttelmann B., Kolczewski S., Peters J. U., Prinssen E., Wichmann J., Vieira E., Muhlemann A., Gatti S., Mutel V. & Malherbe P. (2005) Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. Journal of Pharmacology and Experimental Therapeutics 315, 711-21.
12. Ranum L. P. & Day J. W. (2004) Myotonic Dystrophy: RNA pathogensis comes into focus. American Journal of Human Genetics 74, 793-804.
13. Selby L., Zhang C. & Sun Q. Q. (2007) Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein. Neuroscience Letters 412, 227-32.
14. Tassone F., Hagerman R. J., Taylor A. K., Gane L. W., Godfrey T. E. & Hagerman P. J. (2000) Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in fragile X syndrome. American Journal of Human Genetics 66, 6-15.
15. Westmark C. J. & Malter J. S. (2007) FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein. PLoS Biology 5, e52.